Dr. Shawn Ritchie and Dr. Tara Smith will be attending the Canadian Conference on Dementia (CCD) and Canadian Consortium on Neurodengeneration in Aging (CCNA) to meet with collaborators regarding its first-in-class plasmalogen-directed therapy for Alzheimer’s Disease.
MLD attending CCD and CCNA in October 2019
Previous
Previous
MLD's Plasmalogen Drug PPI-1040 for RCDP receives FDA Orphan Drug Designation (ODD)
Next
Next